Biotech Values

[crudeoil24]

( ISEE ) Iveric Bio Reports Positive Zimura Trial Results, Shares Soar
6:33 am ET September 6, 2022 (Dow Jones) Print
By Dean Seal


Iveric Bio Inc. said Tuesday that a second Phase 3 clinical trial for its geographic atrophy treatment Zimura met its primary endpoint with statistical significance and a favorable safety profile.

The biopharmaceutical company said the two trials have shown a significant reduction in the rate of geographic atrophy progression at the 12-month endpoint.

Iveric said it plans to submit a new drug application for Zimura by the end of the first quarter of 2023.

Shares soared 42% to $13.38 in premarket trading.

ISEE